Belite Bio to Participate in the Leerink Global Healthcare Conference
Belite Bio (NASDAQ: BLTE) will participate in a fireside chat at the Leerink Global Healthcare Conference on Monday, March 9, 2026 at 1:00 pm ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Belite Bio (NASDAQ: BLTE) will participate in a fireside chat at the Leerink Global Healthcare Conference on Monday, March 9, 2026 at 1:00 pm ET. A live webcast is available via the company's investor relations Events page, with replays archived for 90 days.
Details
News Market Reaction – BLTE
On Mar 2, the day this news came out, BLTE closed 6.68% below the previous close.
Data tracked by StockTitan Argus for the Mar 2 session.
Key Figures
- Conference date
- March 9, 2026
- Leerink Global Healthcare Conference fireside chat
- Presentation time
- 1:00 pm ET
- Scheduled time for Leerink conference fireside chat
- Replay duration
- 90 days
- Webcast replays archived after presentation date
Historical Context
-
Announced webcast to discuss preliminary Q4 and full-year 2025 results.
-
Participation at APAO Congress with Phase 3 DRAGON topline data presentations.
-
Completion of enrollment in Phase 2/3 DRAGON II trial for STGD1.
-
Pricing of $350m ADS underwritten public offering at $154 per ADS.
-
Announcement of proposed underwritten ADS offering for corporate purposes.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Leerink Global Healthcare Conference on Monday, March 9, 2026 at 1:00 pm ET.
Webcast Link Instructions
A webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook,or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Sophie Hunt
belite@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.